Assessing the barriers to image-guided drug delivery

Gregory M. Lanza, Chrit Moonen, James R. Baker, Esther Chang, Zheng Cheng, Piotr Grodzinski, Katherine Ferrara, Kullervo Hynynen, Gary Kelloff, Yong Eun Koo Lee, Anil K. Patri, David Sept, Jan E. Schnitzer, Bradford J. Wood, Miqin Zhang, Gang Zheng, Keyvan Farahani

Research output: Contribution to journalArticlepeer-review

44 Scopus citations


Imaging has become a cornerstone for medical diagnosis and the guidance of patient management. A new field called image-guided drug delivery (IGDD) now combines the vast potential of the radiological sciences with the delivery of treatment and promises to fulfill the vision of personalized medicine. Whether imaging is used to deliver focused energy to drug-laden particles for enhanced, local drug release around tumors, or it is invoked in the context of nanoparticle-based agents to quantify distinctive biomarkers that could risk stratify patients for improved targeted drug delivery efficiency, the overarching goal of IGDD is to use imaging to maximize effective therapy in diseased tissues and to minimize systemic drug exposure in order to reduce toxicities. Over the last several years, innumerable reports and reviews covering the gamut of IGDD technologies have been published, but inadequate attention has been directed toward identifying and addressing the barriers limiting clinical translation. In this consensus opinion, the opportunities and challenges impacting the clinical realization of IGDD-based personalized medicine were discussed as a panel and recommendations were proffered to accelerate the field forward.

Original languageEnglish
Pages (from-to)1-14
Number of pages14
JournalWiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology
Issue number1
StatePublished - Jan 2014


Dive into the research topics of 'Assessing the barriers to image-guided drug delivery'. Together they form a unique fingerprint.

Cite this